Navigation Links
Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma
Date:6/22/2011

VIENNA, June 22, 2011 /PRNewswire/ --


 

Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). It is presently under investigation in a phase III trial across various European clinical centers. In return, Apeiron obtains the rights to file for regulatory approval and to market the final product. The approach is based on a monoclonal antibody (ch14.18) and constitutes Apeiron's most advanced project. It also marks another milestone for the company and its development strategy to treat neuroblastoma. This strategy was initiated earlier this year with the licensing of a clinical phase II project from Merck KGaA.

Today, Vienna based Apeiron announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

The Austrian company Polymun Scientific, a long-time business partner of Apeiron, has already been producing clinical supplies for the CCRI/SIOPEN sponsored clinical studies. Apeiron has now commissioned Polymun to continue production and to prepare for manufacture of material at market standard.

Dr. Hans Loibner, CEO of Apeiron: „This novel form of collaboration with CCRI and SIOPEN is a milestone for Apeiron. These non-profit organizations have accomplished remarkable clinical development achievements which we can now complement with our industrial know-how. With this collaboration, we add a project to our portfolio that is both innovative and close to the market."

Professor Ruth Ladenstein, head of the coordination center for clinical studies at CCRI, senior physician at St. Anna Kinderspital and European president of SIOP: „We are convinced to have found an ideal partner in Apeiron. Together, we will take the final steps of development for an urgently needed therapy against high-risk neuroblastoma. By applying immune therapy and other treatment improvements, we hope to increase the chances of survival for children with high-risk neuroblastoma by 30%, thereby rendering future survival rates of 60-70% realistic."

Financial details were not disclosed.

Jacqueline Bogdanovic
+43-1-505-70-44
bogdanovic@prd.at
[contact@prd.at ]
http://http://www.prd.at



'/>"/>
SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
2. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
3. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
6. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
7. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
8. Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
10. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
11. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):